6P8-16920-31182 · OpenVSafe

Timeline

Registration Vaccinations Survey responses Call reports Cases without a report Call attempts Call successful Pregnancy survey

2020-12-21
Registered in v-safe
2020-12-21
Dose 1 — Pfizer-BioNTech
2020-12-21
Health check-in — day 0, dose 1
Feeling: Good · None

Adult check-in
2020-12-22
Health check-in — days 1–6 daily, dose 1
Feeling: Good · None

Adult check-in
2020-12-27
Survey response — days 1–6 daily, dose 1
MedDRA: Disturbance in attention — Feeling: Fair · Fatigue or tiredness, Nausea

Free text: Decreased concentration

MedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
2020-12-28
Survey response — day 7, dose 1
MedDRA: Disturbance in attention — Feeling: Fair · Nausea

Free text: Decreased concentration

MedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
2021-01-04
Health check-in — day 14, dose 1
Feeling: Good

Adult check-in
2021-01-18
Dose 2 — Pfizer-BioNTech
2021-02-01
Health check-in — day 14, dose 2
Feeling: Good

Adult check-in
2021-02-08
Health check-in — day 21, dose 2
Feeling: Good

Adult check-in
2021-02-15
Health check-in — day 28, dose 2
Feeling: Good

Adult check-in
2021-02-22
Survey response — day 35, dose 2
MedDRA: Fatigue, Mental disorder — Feeling: Fair

Free text: Extremely fatigued with decreased mentation slowing since last injection 1/21. At first after the injection, it slowly improved but over the last two weeks it has worsened. I have no other signs of illness or symptoms. I know of no Covid exposure.

MedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
2021-04-19
Survey response — 3 months, dose 2
MedDRA: Disturbance in attention, Dyspnoea, Fatigue, Headache — Feeling: Good

Free text: Had vague headache, fatigue, shortness of breath, and decreased concentration for about 5 weeks that has almost improved over the last several weeks. Onset was about a week later. No fever, purpura, or petechia.

MedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
2021-07-21
Survey response — 6 months, dose 2
MedDRA: Abdominal pain, Exposure to SARS-CoV-2, Lipase increased — Feeling: Good · Get care from a doctor or other healthcare professional · Outpatient clinic or urgent care clinic visit

Free text: Elevated Lipase and abdominal pain after Covid exposure now resolved.

MedDRA releases: 2024-11 · check-in free text available
2021-07-21
Report sent to call center — 6 months, dose 2
Get care from a doctor or other healthcare professional

1 call case(s)
2021-07-27
Call 1 — Left Voicemail

Vaccinations

Dose	Date	Manufacturer	Co-administered
1	2020-12-21	Pfizer-BioNTech
2	2021-01-18	Pfizer-BioNTech

Call center

1 call center case

1 unsuccessful

See the call center timeline

Free text

Release 1 — days 1–6 daily, dose 1

2020-12-27

Systemic reaction (other): Decreased concentration

Release 1 — day 7, dose 1

2020-12-28

Systemic reaction (other): Decreased concentration

Release 4 — day 35, dose 2

2021-02-22

Symptoms: Extremely fatigued with decreased mentation slowing since last injection 1/21. At first after the injection, it slowly improved but over the last two weeks it has worsened. I have no other signs of illness or symptoms. I know of no Covid exposure.

Release 7 — 3 months, dose 2

2021-04-19

Symptoms: Had vague headache, fatigue, shortness of breath, and decreased concentration for about 5 weeks that has almost improved over the last several weeks. Onset was about a week later. No fever, purpura, or petechia.

Release 9 — 6 months, dose 2

2021-07-21

Symptoms: Elevated Lipase and abdominal pain after Covid exposure now resolved.

Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".

MedDRA terms by release

Field	Preferred term	2021-09	2023-04	2024-11
SD	Abdominal pain	·	·	✓
SD	Disturbance in attention	✓	✓	✓
SD	Dyspnoea	✓	✓	✓
SD	Exposure to SARS-CoV-2	·	·	✓
SD	Fatigue	✓	✓	✓
SD	Headache	✓	✓	✓
SD	Lipase increased	·	·	✓
SD	Mental disorder	✓	✓	✓
SRO	Disturbance in attention	✓	✓	✓

✓ active code · ○ coded but marked inactive · blank = not in that release